JP2019528285A - 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法 - Google Patents

抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法 Download PDF

Info

Publication number
JP2019528285A
JP2019528285A JP2019509555A JP2019509555A JP2019528285A JP 2019528285 A JP2019528285 A JP 2019528285A JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019509555 A JP2019509555 A JP 2019509555A JP 2019528285 A JP2019528285 A JP 2019528285A
Authority
JP
Japan
Prior art keywords
antibody
nkg2d
disease
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019509555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528285A5 (enExample
Inventor
ブロッドマーケル，キャリー
カラン，マーク
グリーンバウム，リンダ
テレスコ，シャノン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2019528285A publication Critical patent/JP2019528285A/ja
Publication of JP2019528285A5 publication Critical patent/JP2019528285A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019509555A 2016-08-19 2017-08-17 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法 Pending JP2019528285A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377358P 2016-08-19 2016-08-19
US62/377,358 2016-08-19
PCT/US2017/047357 WO2018035330A1 (en) 2016-08-19 2017-08-17 Methods of treating crohn's disease with an anti-nkg2d antibody

Publications (2)

Publication Number Publication Date
JP2019528285A true JP2019528285A (ja) 2019-10-10
JP2019528285A5 JP2019528285A5 (enExample) 2020-08-27

Family

ID=61197073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019509555A Pending JP2019528285A (ja) 2016-08-19 2017-08-17 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法

Country Status (9)

Country Link
US (1) US20190292265A1 (enExample)
EP (1) EP3500293A4 (enExample)
JP (1) JP2019528285A (enExample)
KR (1) KR20190038919A (enExample)
AU (1) AU2017312049A1 (enExample)
CA (1) CA3034324A1 (enExample)
MA (1) MA45997A (enExample)
MX (1) MX2019001958A (enExample)
WO (1) WO2018035330A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777A (zh) * 2021-12-01 2023-06-02 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
EP3797120A1 (en) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
CA3105464A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
CN112578124A (zh) * 2019-09-27 2021-03-30 廖睿 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
EP4448761A1 (en) 2021-12-16 2024-10-23 Valerio Therapeutics New conjugated nucleic acid molecules and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266432A1 (en) * 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
WO2011082382A2 (en) * 2009-12-31 2011-07-07 The Trustees Of Columbia University In The City Of New York Methods for detecting and regulating alopecia areata and gene cohorts thereof
RU2017129455A (ru) * 2015-01-26 2019-03-04 Селлектис Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALLEZ, M. ET AL.: "Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled tri", GUT, vol. 66, no. 11, JPN6021024499, 3 August 2016 (2016-08-03), pages 1918 - 1925, XP009513618, ISSN: 0004701415, DOI: 10.1136/gutjnl-2016-311824 *
ALLEZ, M. ET AL.: "P-097 Novel Anti-NKG2D Monoclonal Antibody (NNC0142-0002) in Crohn's Disease: An Analysis of Patient", INFLAMMATORY BOWEL DISEASES, vol. 20, no. 1, JPN6021024497, December 2014 (2014-12-01), pages 66 - 67, ISSN: 0004701416 *
KABALAK, G. ET AL.: "Association of an NKG2D gene variant with systemic lupus erythematosus in two populations", HUMAN IMMUNOLOGY, vol. 71, no. 1, JPN6021024494, 2010, pages 74 - 78, XP026794738, ISSN: 0004701418 *
MIRIAM, E. ET AL.: "93-P MIC AND NKG2D GENES POLYMORPHISM IN MEXICAN POPULATION", HUMAN IMMUNOLOGY, vol. 74, JPN6021024493, 2013, pages 116, ISSN: 0004701419 *
PATHAN, S. ET AL.: "O-48 A case-control investigation using tag SNPs with Crohn’s disease that span across the MHC clas", TISSUE ANTIGENS, vol. 69, no. 5, JPN6021024491, 2007, pages 392 - 373, ISSN: 0004701420 *
児矢野 聡 ほか: "全ゲノム網羅的SNP解析によるインフリキシマブあるいはエタネルセプト治療関節リウマチ患者の有効性、副作", 臨床リウマチ, vol. 第21巻, 第4号, JPN6021024495, 2009, pages 399 - 405, ISSN: 0004701417 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777A (zh) * 2021-12-01 2023-06-02 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Also Published As

Publication number Publication date
WO2018035330A1 (en) 2018-02-22
US20190292265A1 (en) 2019-09-26
EP3500293A1 (en) 2019-06-26
EP3500293A4 (en) 2020-08-19
MX2019001958A (es) 2019-06-13
KR20190038919A (ko) 2019-04-09
MA45997A (fr) 2019-06-26
AU2017312049A1 (en) 2019-02-21
CA3034324A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
US20220289858A1 (en) Anti-cd40 antibodies and uses thereof
JP2019528285A (ja) 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法
JP6638018B2 (ja) Ｆｃレセプター結合タンパク質
TWI468174B (zh) 針對人類ｎｋｇ２ｄ的抗體及其用途
KR20210005169A (ko) 최적화된 항tl1a 항체
TW201902915A (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
BRPI0712953A2 (pt) anticorpos anti-nkg2a e suas utilizações
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
JP2016528247A (ja) 孤発性封入体筋炎を治療する方法
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
JP7681069B2 (ja) 抗ペリオスチン抗体及びその使用
CN115768525A (zh) 用于治疗癌症的组合物和方法
JP2022529985A (ja) 抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法
TWI811216B (zh) 治療兒科病症之方法
CA3194339A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
TW202124432A (zh) 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法
JP2022529970A (ja) 抗ｐｓｍａ／ｃｄ３抗体で腎癌を治療する方法
JP2022553803A (ja) 血液がんの処置のための診断方法及び治療方法
US20250179182A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody drug conjugate
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208